|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 6,770 HKD | -1,46% |
|
-2,03% | +111,56% |
| 04/12 | Sino Biopharm Krijgt Goedkeuring van Chinese en Amerikaanse FDA voor Proeven met Afslankmiddel | MT |
| 04/12 | Sino Biopharmaceutical: TQF3250-klinische proef goedgekeurd door NMPA en FDA | RE |
Voorlopige winst- en verliesrekening: Sino Biopharmaceutical Limited
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 23.647 | 26.861 | 28.780 | 26.199 | 28.866 | 33.019 | 36.071 | 40.191 |
| Variatie | - | 13,59% | 7,14% | -8,97% | 10,18% | 14,39% | 9,24% | 11,42% |
| EBITDA 1 | 5.753 | 5.174 | 6.908 | 6.476 | 6.490 | 9.337 | 9.788 | 10.591 |
| Variatie | - | -10,07% | 33,52% | -6,26% | 0,22% | 43,87% | 4,83% | 8,2% |
| Bedrijfsresultaat (EBIT) 1 | 4.098 | 4.182 | 5.861 | 5.439 | 5.169 | 7.740 | 8.220 | 9.248 |
| Variatie | - | 2,03% | 40,17% | -7,2% | -4,97% | 49,74% | 6,21% | 12,5% |
| Betaalde rente 1 | -323,4 | -308,6 | -439,1 | -495,2 | -295,1 | -239,5 | -222,9 | -202,1 |
| Resultaat voor belastingen (EBT) 1 | 5.013 | 18.573 | 5.779 | 5.215 | 5.277 | 9.554 | 9.387 | 10.181 |
| Variatie | - | 270,49% | -68,89% | -9,76% | 1,2% | 81,04% | -1,75% | 8,46% |
| Nettowinst (verlies) 1 | 2.771 | 14.608 | 2.544 | 2.332 | 3.500 | 4.723 | 4.710 | 5.116 |
| Variatie | - | 427,17% | -82,59% | -8,32% | 50,08% | 34,96% | -0,28% | 8,63% |
| Datum van publicatie | 23-03-21 | 31-03-22 | 31-03-23 | 28-03-24 | 20-03-25 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Balansprognose: Sino Biopharmaceutical Limited
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuld 1 | -1.266 | -3.107 | -1.915 | 2.742 | 13 | -5.967 | -12.046 | -18.311 |
| Variatie | - | -145,42% | 38,36% | 243,19% | -99,53% | -46.024,73% | -101,88% | -52,01% |
| Datum van publicatie | 23-03-21 | 31-03-22 | 31-03-23 | 28-03-24 | 20-03-25 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Verwachte kasstroom: Sino Biopharmaceutical Limited
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 1.582 | 1.561 | 1.760 | 2.643 | 2.754 | 1.267 | 1.433 | 1.500 |
| Variatie | - | -1,33% | 12,73% | 50,17% | 4,21% | -53,99% | 13,06% | 4,7% |
| Vrije kasstroom (FCF) 1 | 3.743 | 3.805 | 4.505 | 3.423 | 3.861 | 6.458 | 6.774 | 7.965 |
| Variatie | - | 1,66% | 18,4% | -24,03% | 12,8% | 67,27% | 4,9% | 17,58% |
| Datum van publicatie | 23-03-21 | 31-03-22 | 31-03-23 | 28-03-24 | 20-03-25 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Verwachte financiële ratio's: Sino Biopharmaceutical Limited
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
| EBITDA-marge (%) | 24,33% | 19,26% | 24% | 24,72% | 22,48% | 28,28% | 27,14% | 26,35% |
| EBIT-marge (%) | 17,33% | 15,57% | 20,37% | 20,76% | 17,91% | 23,44% | 22,79% | 23,01% |
| EBT-marge (%) | 21,2% | 69,14% | 20,08% | 19,9% | 18,28% | 28,94% | 26,02% | 25,33% |
| Nettomarge (%) | 11,72% | 54,38% | 8,84% | 8,9% | 12,12% | 14,31% | 13,06% | 12,73% |
| FCF-marge (%) | 15,83% | 14,17% | 15,65% | 13,06% | 13,37% | 19,56% | 18,78% | 19,82% |
| Vrije kasstroom/nettoresultaat (%) | 135,08% | 26,05% | 177,12% | 146,78% | 110,31% | 136,73% | 143,83% | 155,68% |
Winstgevendheid | ||||||||
| ROA | 6,54% | 27,11% | 4,08% | 3,65% | 5,43% | 7,31% | 7,11% | 7,27% |
| ROE | 17,49% | 62,11% | 8,47% | 7,74% | 11,21% | 13,69% | 12,01% | 12,15% |
Financiële gezondheid | ||||||||
| Hefboom (schuld/ebitda) | - | - | - | 0,42x | 0x | - | - | - |
| Schuld/vrije kasstroom | - | - | - | 0,8x | 0x | - | - | - |
Kapitaalintensiteit | ||||||||
| Kapitaaluitgaven/omzet (%) | 6,69% | 5,81% | 6,12% | 10,09% | 9,54% | 3,84% | 3,97% | 3,73% |
| CAPEX / EBITDA (%) | 27,5% | 30,17% | 25,48% | 40,81% | 42,44% | 13,57% | 14,64% | 14,16% |
| CAPEX / FCF (%) | 42,27% | 41,03% | 39,06% | 77,21% | 71,34% | 19,62% | 21,15% | 18,83% |
Bestanddelen per aandeel | ||||||||
| Kasstroom per aandeel 1 | 0,2833 | 0,2859 | 0,3294 | 0,3274 | 0,3616 | 0,4604 | 0,5084 | 0,5574 |
| Variatie | - | 0,92% | 15,22% | -0,61% | 10,45% | 27,31% | 10,44% | 9,62% |
| Dividend per aandeel 1 | 0,0671 | 0,0648 | 0,105 | 0,0462 | 0,0653 | 0,0836 | 0,086 | 0,0923 |
| Variatie | - | -3,52% | 62,15% | -55,96% | 41,12% | 28,04% | 2,93% | 7,28% |
| Nettoactief per aandeel 1 | 0,89 | 1,614 | 1,611 | 1,621 | 1,701 | 1,975 | 2,138 | 2,331 |
| Variatie | - | 81,34% | -0,2% | 0,63% | 4,93% | 16,14% | 8,25% | 9% |
| WPA 1 | 0,1474 | 0,7326 | 0,1215 | 0,1259 | 0,1913 | 0,2482 | 0,2606 | 0,2962 |
| Variatie | - | 397,01% | -83,42% | 3,62% | 51,95% | 29,77% | 4,96% | 13,68% |
| Aantal aandelen (in duizend) | 18.789.999 | 18.756.114 | 18.481.249 | 18.399.239 | 18.205.469 | 17.876.722 | 17.876.722 | 17.876.722 |
| Datum van publicatie | 23-03-21 | 31-03-22 | 31-03-23 | 28-03-24 | 20-03-25 | - | - | - |
1CNY
Geschatte gegevens
| 2025 * | 2026 * | |
|---|---|---|
| k/w-verhouding | 24,8x | 23,6x |
| PBR-ratio | 3,11x | 2,87x |
| EV/omzet | 3,15x | 2,71x |
| Dividendrendement | 1,36% | 1,4% |
Meer waarderingsratio's
* Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Trader
Trader
Beleggings
Beleggings
Globaal
Globaal
Kwaliteit van de publicaties
Kwaliteit van de publicaties
ESG MSCI
A
Verkoop
Koop
Gemiddeld advies
Kopen
Aantal analisten
26
Laatste slotkoers
6,145CNY
Gemiddelde koersdoel
8,662CNY
Spread / Gemiddelde doel
+40,96%
Kwartaalomzet - Afwijkingspercentage
- Beurs
- Aandelen
- Koers 1177
- Financiën Sino Biopharmaceutical Limited
Kies jouw editie
Alle financiële informatie op nationaal niveau
